Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 21 (TRAV21) encodes a variable segment of the T cell receptor (TCR) alpha chain, which is essential for antigen recognition by αβ T cells. The TCR, comprising alpha (TRA) and beta (TRB) chains, recognizes processed foreign antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, triggering cell-mediated immune responses[1][2]. TRAV21 is one of many gene segments that are somatically recombined during T cell development to yield a diverse repertoire of TCRs, enabling recognition of a vast range of antigens. The variable domain, including CDR (complementarity determining regions), directly interacts with peptide-MHC complexes, contributing to T cell specificity and function[1][3]. While TRAV21 is not a therapeutic target per se, it can play a role in immunotherapies where defined TCR variable regions are engineered for specificity, such as in adoptive T cell therapies[3].
Not applicable at this resolution (no drugs are known to target TRAV21 specifically; its mechanism is via *antigen recognition* as a TCR alpha variable segment)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 21 (TRAV21).